



PATENT
Customer No. 22,852
Attorney Docket No. 6832.0016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Craig A. ROSEN et al.) Group Art Unit: 1653
)
Application No.: 09/833,041) Examiner: Hope A. Robinson
)
Filed: April 12, 2001) Confirmation No.: 2391
)
For: ALBUMIN FUSION PROTEINS)

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

SIR:

Applicants enclose a substitute computer readable form of the Sequence Listing and a substitute paper copy of the Sequence Listing to correct errors in the Sequence Listing.

Specifically, the sequences corresponding to SEQ ID NOs: 19 and 20 are correctly listed in the specification on page 244 but the Sequence Listing inadvertently omitted a "G" and a "C" at the end of the sequences, respectively. The Sequence Listing was amended to add the omitted nucleotides.

Additionally, the original Sequence Listing listed SEQ ID NOs: 36-71 as corresponding to those sequences depicted in Table 3 (page 315) of the specification. However, the sequence identifiers SEQ ID NOs: 36-45 were also used for different

sequences listed on pages 259-260, 285, 287, 290, and 292-293, and were not listed in the original Sequence Listing. Therefore, these omitted sequences have been added to the attached substitute Sequence Listing as SEQ ID NOs: 81-90. The specification has also been amended by virtue of the concurrently-filed Amendment to identify these sequences as SEQ ID NOs: 81-90.

The sequence corresponding to Therapeutic Protein HNHFE71 listed as SEQ ID NO: 79 in Table 1, page 36, was also inadvertently omitted from the original Sequence Listing. As discussed in the concurrently-filed Amendment, the sequence for HNHFE71 was disclosed prior to the filing date of the instant application in WO 00/61625 (published Oct. 19, 2000) (enclosed with the concurrently-filed Supplemental IDS) at page 88 and as SEQ ID NO: 101. The sequence for HNHFE71 has been added as SEQ ID NO: 80 in the attached substitute Sequence Listing and the specification has also been amended to recite SEQ ID NO: 80 rather than SEQ ID NO: 79.

Thus, no new matter has been added.

In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission does not include new matter; and
2. the content of the paper copy of the Substitute Sequence Listing and of the computer readable copy of the Substitute Sequence Listing are the same.

Should any fees be required to comply with this requirement, please charge our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Charles E. Van Horn
Charles E. Van Horn
Reg. No. 40,266

Dated: May 18, 2004